ConductScience.org, home

Comparison · NCT03691831-2ca110d4

Active vs Vehicle: Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Active vs Vehicle: Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60). Trial comparisons, record NCT03691831-2ca110d4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03691831-2ca110d4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1510.09870.224wilson
Risk in group 20.02820.0110.0702wilson
Risk difference, group 1 minus group 20.1230.05570.197newcombe hybrid score
Risk ratio, group 1 over group 25.351.8715.3log
Odds ratio, group 1 over group 26.132.0218.5log
Number needed to treat, for one more participant with the outcome on Active than on Vehicle8.155.0718from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1ActiveTopical solution, hydrogen peroxide 45%~A-101: hydrogen peroxide 45% topical solution19126OG000
Group 2VehicleTopical solution, isopropyl alcohol and water~Vehicle: Vehicle solution containing isopropyl alcohol and water4142OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With a Single Wart at Baseline Whose Wart Was Clear on the PWA Scale Between Active and Vehicle Group (PWA=0) at Visit 10 (Day 60)
Description
Comparison between Active (A-101 45%) and Vehicle of subjects with a single wart at baseline, whose wart is clear (PWA=0) at Day 60.~Clearance of the single wart at baseline will be assessed using the Physician Wart Assessment (PWA) scale which is a four point scale. A higher amount of warts cleared represents a better outcome.
Time frame
Day 60
Population

Source ClinicalTrials.gov

Trial

Title
A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT number
NCT03691831
Phases
PHASE3
Conditions
Common Wart
Interventions
Active, Vehicle
Lead sponsor
Aclaris Therapeutics, Inc.
Results first posted
2020-10-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03691831-2ca110d4